Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”
Abstract
The treatment landscape for metastatic renal cell carcinoma (mRCC) has changed significantly with the advent of combination therapies based on immune checkpoint inhibitors (ICIs). Currently, nivolumab plus ipilimumab (NIVO+IPI) and ICI plus tyrosine kinase inhibitor (IO–TKI) combination therapies are widely used as first-line treatments. NIVO+IPI, in particular, produces deep and durable responses in some patients. The final analysis of the CheckMate 214 trial, which included a follow-up period of more than 9 years, also confirmed the long-term survival benefit of NIVO+IPI compared with sunitinib [1, 2]. However, not all patients benefit from this sustained antitumor effect. Numakura and Abe have published a timely review focusing on primary resistance to NIVO+IPI, which is observed in approximately 20%–25% of patients [1]. This review comprehensively summarizes mechanisms potentially involved in primary resistance, including an immunosuppressive tumor microenvironment, metabolic reprogramming, abnormalities in interferon signaling